Editorial

Adverse Drug Effects and Pegylation

Authors: James M. Wooten, PharmD

Abstract

Adverse drug reactions (ADRs) are commonplace these days. With so many pharmaceuticals used to treat so many varied diseases in patients of varying types, it is no wonder that ADR case reports have become common. In this issue of the Southern Medical Journal Ji et al1 document a case of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C virus (HCV) infection. This case is interesting on two fronts. First, hepatitis C is a major health issue worldwide, with an estimated 170 million people infected.2 Second, various drugs may be beneficial in treating hepatitis C, but interferon remains a mainstay of therapy. Understanding and documenting potential adverse effects from a commonly used treatment modality is vital to anticipating potential ADRs and preventing their occurrence.3

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Ji F, Li Z, Xue H, et al. Simultaneous occurrence of pleural effusion and interstitial pneumonitis after treatment with pegylated interferon for hepatitis C infection. South Med J 2010;104:140–142.
 
2. World Hepatitis Alliance. Hepatitis B & C: fast facts. Available at: http://www.worldhepatitisalliance.org/Libraries/English_Fact_Sheets/2010_Hepatitis_B_and_C_Fact_Sheet.sflb.ashx. Accessed October 8, 2010.
 
3. Pockros PJ. Attacking the hepatitis C virus with new mechanisms of action: drugs in the pipeline. The HCV Advocate Medical Writers' Circle 2004;May:1–4. Available at: http://www.hcvadvocate.org/hcsp/hcsp_pdf/Pockros_4.pdf. Accessed October 8, 2010.
 
4. Friedman RM, Contente S. Treatment of hepatitis C infections with interferon: a historical perspective.Hepatitis Res Treatment 2010;1:1–4. Available at: http://downloads.hindawi.com/journals/heprt/2010/323926.pdf. Accessed October 7, 2010.
 
5. Bryan J. Interferon: an important step forward in treating hepatitis C infection. Pharmcol J2008;280:753–4. Available at: http://www.pharmj.com/pdf/articles/pj_20080621_interferon.pdf. Accessed October 7, 2010.
 
6. Clark V, Nelson DR. Novel interferons for treatment of hepatitis C virus. Clin Liver Dis 2009;13:351–363.
 
7. Veronese FM, Mero A. The Impact of pegylation on biological therapies. BioDrugs 2008;22:315–329.
 
8. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J 2010;5:113–128.
 
9. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539–551.
 
10. Abi-Nassif S, Mark EJ, Fogel RB, et al. Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS. Chest 2003;124:406–410.
 
11. Berg T. Tailored treatment for hepatitis C. Clin Liver Dis 2008;12:507–528.
 
12. Rock M. The weakest link: looking at the toxicity challenges of biologic drug linkers. Eur Pharm Rev 2008;1:49–51.
 
13. Kang JS, DeLuca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs 2009;14:364–380.
 
14. Singal AK. Type of pegylated interferon matters: another milestone in the treatment of hepatitis C virus infection. Hepat Mon 2010;10:165–167.